As a result, CTLA-4-blocking antibodies augment the binding of CD80/86 to CD28 rather than to CTLA-4 and also deplete Tregs in the tumor environment that consistently express CTLA-4 (Fig. 1a)13,14. Here, CTLA4 is linked to neoplasm.